Luspatercept for Lower Risk MDS

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

What's the purpose of the trial?

To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
40
Last Updated
1 month ago
Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Luspatercept is an agent that helps your bone marrow finish making red blood cells that have started to form.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

EXPERIMENTAL: Cohort 1

Accepting patients

EXPERIMENTAL: Cohort 2

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.